Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53. [electronic resource]
Producer: 20200601Description: e19 p. digitalISSN:- 1873-7560
No physical items for this record
Publication Type: Letter; Comment
There are no comments on this title.
Log in to your account to post a comment.